Ipilimumab, initially approved for treatment of stage III/IV melanoma, achieves therapeutic action by blocking the cytotoxic T lymphocyte antigen 4 (CTLA-4) from binding to its ligands B7.1 and B7.2, effectively functioning as an inhibitor of IL-2 production and T-cell differentiation [55]. This evidence concerns the gene CTLA4 and melanoma.